Engineering an immunotherapy to outwit cancer — and launch a biotech

Engineering an immunotherapy to outwit cancer — and launch a biotech

STAT Plus: Engineering a better immunotherapy to outwit cancer — and launch a biotech

By ELIZABETH COONEY

A. WALKER, L. SHARP & J. PRYDE/WELLCOME

Tweaking an immune protein called interleukin-18 can overcome tumors that lure it into binding with a decoy receptor protein, new research in mice shows.

READ MORE